Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts....
+See More2019-05-21 12:37:00 Tuesday ET
Chicago finance professor Raghuram Rajan shows that free markets need populist support against an unholy alliance of private-sector and state elites. When a
2019-07-30 15:33:00 Tuesday ET
All of the 18 systemically important banks pass the annual Federal Reserve stress tests. Many of the largest lenders announce higher cash payouts to shareho
2018-05-17 07:41:00 Thursday ET
Has America become a democratic free land of crumbling infrastructure, galloping income inequality, bitter political polarization, and dysfunctional governa
2018-10-30 10:41:00 Tuesday ET
Personal finance author Ramit Sethi suggests that it is important to invest in long-term gains instead of paying attention to daily dips and trends. It
2018-06-04 08:38:00 Monday ET
Microsoft acquires GitHub, a software development platform that has been widely shared-and-used by more than 28 million programmers worldwide. GitHub's
2019-08-05 13:30:00 Monday ET
China continues to sell U.S. Treasury bonds amid Sino-U.S. trade truce uncertainty. In mid-2019, China reduces its U.S. Treasury bond positions by $20.5 bil